Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 36Cholangiocarcinoma 11Carcinoma, Renal Cell 10Stomach Neoplasms 5Liver Neoplasms 5Neoplasms 4Endometrial Neoplasms 4Biliary Tract Neoplasms 4Uterine Cervical Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Vulvar Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Recurrence 2Ovarian Neoplasms 2Neoplasm Metastasis 2Liver Diseases 2Kidney Neoplasms 2Cirrhosis, Familial, with Pulmonary Hypertension 2Breast Neoplasms 2Advanced Solid Tumor 2von Hippel-Lindau Disease 1Urogenital Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Solid Tumor, Adult 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Penile Neoplasms 1

Interventions

pembrolizumab 1lenvatinib 1enfortumab vedotin 1abemaciclib 1Tablets 1Standard of Care 1Radiosurgery 1Protons 1Nivolumab 1Epirubicin 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Adenoid Cystic × lenvatinib × Clear all
NCT05774899 2025-06-17

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
32 enrolled

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡